https://www.ncbi.nlm.nih.gov/pubmed/31663387 Hepatitis B
Expert Rev Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1080/17474124.2019.1686975. [Epub ahead of print]
Updates in the management of hepatitis B in children.
Lai MW1,2,3, Chang MH4.

Abstract

Introduction: Universal infant hepatitis B virus (HBV) vaccination program has reduced HBV infection dramatically in vaccinated young generations. Management of chronically infected children is still challenging concerning high viral load with mostly mild diseases, yet with a nonnegligible proportion of advanced diseases, and long-term effect of antivirals. However, with more potent antivirals approved for pediatric patients, to start antivirals earlier in eligible patients may benefit their outcomes. This review aimed to update the current management of chronic hepatitis B in children.Areas covered: This review covered the natural history of chronic HBV infection, management of chronic hepatitis B in children from the past to the present, current consensus on the treatment of chronic hepatitis B in children, controversies in cessation of oral antivirals, and management of special populations such as pregnancy and co-infections.Expert opinions: Without contraindication, peginterferon is recommended for immune-active children ≥ 3 years old. For those intolerant, decompensating or preferring oral therapy, first-line Nucleos(t)ide analogs (NUC), Entecavir or Tenofovir, may be applied. For immune-tolerant or inactive carriers, close monitoring is crucial. When to stop NUCs and novel therapies for HBV cure await further research.

KEYWORDS:
HBeAg seroconversion; HBeAg-negative hepatitis; HBsAg loss; immune clearance; immune tolerant; liver fibrosis; nucleos(t)ide analogs; pegylated interferon; reactivation